Apparently undaunted by Alvotech’s recent challenges in the US, Teva has made a renewed commitment to its partnership with the Icelandic biosimilars developer that will involve the Israeli firm getting more involved in Alvotech’s manufacturing remediation efforts, as well as making a $40m investment in Alvotech and the pair adding two further biosimilar candidates to their existing partnered portfolio.
First announced almost three years ago, Teva’s alliance with Alvotech originally spanned five biosimilars, representing “one of the broadest partnerships...
